Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia)

被引：11

作者：

Sakai, Tetsuya ^{[1
]}

Matsumoto, Shingo ^{[1
]}

Ueda, Yasuto ^{[2
]}

Shibata, Yuji ^{[1
]}

Ikeda, Takaya ^{[1
]}

Nakamura, Atsushi ^{[3
]}

Kodani, Masahiro ^{[4
]}

Ohashi, Kadoaki ^{[5
]}

Furuya, Naoki ^{[6
]}

Izumi, Hiroki ^{[1
]}

Nosaki, Kaname ^{[1
]}

Umemura, Shigeki ^{[1
]}

Zenke, Yoshitaka ^{[1
]}

Udagawa, Hibiki ^{[1
]}

Sugiyama, Eri ^{[1
]}

Yoh, Kiyotaka ^{[1
]}

Goto, Koichi ^{[1
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Thorac Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2770882, Japan

[2] Tottori Prefectural Cent Hosp, Dept Resp Med, Tottori, Japan

[3] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Japan

[4] Tottori Univ, Fac Med, Dept Multidisciplinary Internal Med, Div Resp Med & Rheumatol, Yonago, Japan

[5] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan

[6] St Marianna Univ, Sch Med, Dept Internal Med, Div Resp Med, Kawasaki, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

Non-small cell lung cancer; BRAF mutations; BRAF non-V600E; Next-generation sequencing; BRAF class; Class IIa; CELL LUNG-CANCER; OPEN-LABEL; DABRAFENIB; MULTICENTER; TRAMETINIB; MUTANTS; THERAPY;

D O I：

10.1016/j.jtho.2023.07.024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: BRAF non-V600E mutations occur in 1% to 2% of NSCLCs. Because of their rarity, the clinical back-grounds and outcomes of cytotoxic chemotherapy or immunotherapy remain unclear, and no targeted therapies are approved for BRAF non-V600E-mutant NSCLC.Methods: In this multi-institutional prospective lung cancer genomic screening project (LC-SCRUM-Asia), we evaluated the clinicogenomic characteristics and therapeutic out-comes of BRAF non-V600E-mutant NSCLC.Results: From March 2015 to November 2021, a total of 11,929 patients with NSCLC were enrolled. BRAF mutations were detected in 380 (3.5%), including the V600E (class I) in 119 (31%) and non-V600E in 261; the non-V600E were functionally classified into class II (122, 32%), class III (86, 23%), and non-classes I to III. Smokers and having con-current RAS gene family or TP53 mutations were more frequently associated with class II or III than with class I. In patients with class III as compared with class I, the progression-free survival in response to platinum -containing chemotherapies (median, 5.3 versus 11.5 mo, p < 0.01) and the overall survival (median, 14.5 versus 34.8 mo, p < 0.02) were significantly shorter. Furthermore, class IIa mutations were significantly more frequent in our Asian cohort than in previously reported cohorts. The clin-icogenomic features associated with class IIa were similar to those associated with class I, and one patient with NSCLC with K601E had a good response to dabrafenib plus trametinib.Conclusions: Patients with NSCLCs with BRAF non-V600E, especially class III, were associated with poorer therapeutic outcomes than those with V600E. Furthermore, patients with NSCLC with class IIa had distinct clinicogenomic features, and further preclinical and clinical studies are needed to evaluate class IIa mutations as a therapeutic target.(c) 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

引用

页码：1538 / 1549

页数：12

共 30 条

[11] Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors [J].

Hovelson, Daniel H. ;

McDaniel, Andrew S. ;

Cani, Andi K. ;

Johnson, Bryan ;

Rhodes, Kate ;

Williams, Paul D. ;

Bandla, Santhoshi ;

Bien, Geoffrey ;

Choppa, Paul ;

Hyland, Fiona ;

Gottimukkala, Rajesh ;

Liu, Guoying ;

Manivannan, Manimozhi ;

Schageman, Jeoffrey ;

Ballesteros-Villagrana, Efren ;

Grasso, Catherine S. ;

Quist, Michael J. ;

Yadati, Venkata ;

Amin, Anmol ;

Siddiqui, Javed ;

Betz, Bryan L. ;

Knudsen, Karen E. ;

Cooney, Kathleen A. ;

Feng, Felix Y. ;

Roh, Michael H. ;

Nelson, Peter S. ;

Liu, Chia-Jen ;

Beer, David G. ;

Wyngaard, Peter ;

Chinnaiyan, Arul M. ;

Sadis, Seth ;

Rhodes, Daniel R. ;

Tomlins, Scott A. .

NEOPLASIA, 2015, 17 (04) :385-399

[12] Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts [J].

Li, S. ;

Li, L. ;

Zhu, Y. ;

Huang, C. ;

Qin, Y. ;

Liu, H. ;

Ren-Heidenreich, L. ;

Shi, B. ;

Ren, H. ;

Chu, X. ;

Kang, J. ;

Wang, W. ;

Xu, J. ;

Tang, K. ;

Yang, H. ;

Zheng, Y. ;

He, J. ;

Yu, G. ;

Liang, N. .

BRITISH JOURNAL OF CANCER, 2014, 110 (11) :2812-2820

[13] Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort [J].

Lim, Guan Hui Tricia ;

Balbi, Kevin Jon ;

Poskitt, Benjamin ;

Bennett, Philip ;

Moore, David Allan .

LUNG CANCER, 2022, 173 :71-74

[14] The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients [J].

Lin, Quan ;

Zhang, Haoran ;

Ding, Huaxin ;

Qian, Jun ;

Lizaso, Analyn ;

Lin, Jing ;

Han Han-Zhang ;

Xiang, Jianxing ;

Li, Yuping ;

Zhu, Hong .

JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (01)

[15] BRAF mutations in non-small cell lung cancer [J].

Luk, Peter P. ;

Yu, Bing ;

Ng, Chiu Chin ;

Mercorella, Belinda ;

Selinger, Christina ;

Lum, Trina ;

Kao, Steven ;

O'Toole, Sandra A. ;

Cooper, Wendy A. .

TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (02) :142-148

[16] A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma [J].

Marchand, A. ;

Tallet, A. ;

Collin, C. ;

Cormier, B. ;

Venel, Y. ;

Miquelestorena-Standley, E. ;

Machet, L. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (02) :528-529

[17] Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Harboring BRAF Mutations [J].

Marchetti, Antonio ;

Felicioni, Lara ;

Malatesta, Sara ;

Sciarrotta, Maria Grazia ;

Guetti, Luigi ;

Chella, Antonio ;

Viola, Patrizia ;

Pullara, Carmela ;

Mucilli, Felice ;

Buttitta, Fiamma .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) :3574-3579

[18] Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers [J].

Murciano-Goroff, Yonina R. ;

Pak, Terry ;

Mondaca, Sebastian ;

Flynn, Jessica R. ;

Montecalvo, Joseph ;

Rekhtman, Natasha ;

Halpenny, Darragh ;

Plodkowski, Andrew J. ;

Wu, Stephanie L. ;

Kris, Mark G. ;

Paik, Paul K. ;

Riely, Gregory J. ;

Yu, Helena A. ;

Rudin, Charles M. ;

Hellmann, Matthew D. ;

Land, Josiah D. ;

Buie, Larry W. ;

Heller, Glenn ;

Lito, Piro ;

Yaeger, Rona ;

Drilon, Alexander ;

Liu, Dazhi ;

Li, Bob T. ;

Offin, Michael .

BRITISH JOURNAL OF CANCER, 2022, 126 (06) :889-898

[19] Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations [J].

Negrao, Marcelo, V ;

Raymond, Victoria M. ;

Lanman, Richard B. ;

Robichaux, Jacqulyne P. ;

He, Junqin ;

Nilsson, Monique B. ;

Ng, Patrick K. S. ;

Amador, Bianca E. ;

Roarty, Emily B. ;

Nagy, Rebecca J. ;

Banks, Kimberly C. ;

Zhu, Viola W. ;

Ng, Chun ;

Chae, Young Kwang ;

Clarke, Jeffrey M. ;

Crawford, Jeffrey A. ;

Meric-Bernstam, Funda ;

Ou, Sai-Hong Ignatius ;

Gandara, David R. ;

Heymach, John, V ;

Bivona, Trever G. ;

McCoach, Caroline E. .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) :1611-1623

[20] Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations [J].

Paik, Paul K. ;

Arcila, Maria E. ;

Fara, Michael ;

Sima, Camelia S. ;

Miller, Vincent A. ;

Kris, Mark G. ;

Ladanyi, Marc ;

Riely, Gregory J. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) :2046-2051

← 1 2 3 →